Skip to main content
SpringerLink
Log in

Hormonal Factors and Breast Tumor Proliferation: Do Factors that Affect Cancer Risk also Affect Tumor Growth?

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background. Tumor cell proliferation is one of the most significant predictors of prognosis for women with breast cancer. Personal characteristics that affect hormonal exposure have been implicated in breast tumor etiology, and it is possible that they may also influence tumor cell proliferation. We examined the association between hormone-related breast cancer risk factors and breast tumor proliferation, as reflected in two proliferation measures, Ki-67 and mitotic count.

Methods. The study population was 484 women 40 years of age and older, who were members of a managed care organization's breast cancer screening program and were diagnosed with invasive breast cancer between 1988 and 1995. The percent of Ki-67 positive tumor cells averaged over four high powered fields (Ki-67) was log transformed and analyzed in a linear regression model. Mitotic count was dichotomized into high versus low (≤10), and analyzed in an unconditional logistic regression model with the odds ratio (OR) as the measure of association.

Results. Consistent with other studies, there was a significant trend of decreased tumor cell proliferation with increasing age (p for trend <0.05 for both measures). Higher body weight was associated with higher Ki-67 (p for trend <0.05), but not with higher mitotic count. We found no significant associations between any reproductive factors (age at menarche, parity, age at first birth, menopausal status and age at menopause) and either measure of tumor cell proliferation. We observed an association between reduced tumor proliferation, as measured by mitotic count and former/current use of hormone replacement therapy (HRT) in comparison to never use (adjusted OR's: former HRT use: 0.40 (95% CI 0.19–0.85); current HRT use: 0.52 (95% CI 0.26–1.04).

Conclusion. Certain factors related to hormonal exposure that influence breast tumor etiology, for example, age, also appear to increase tumor growth. Conversely HRT use, which clearly increases breast cancer risk, may not adversely affect, and possibly may diminish cell proliferation once tumors are established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schneider J, Huh MM, Bradlow HL, Fishman J: Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259: 4840–4845, 1984

    Google Scholar 

  2. Noguchi M, Thomas M, Koyasaki N et al.: Influence of hormones on tumor growth, cell kinetics, estrogen receptor and insulin-like growth factor-I-related protein of human breast cancer (MCF-7) cells transplanted in nude mice. Mol Cell Endocrinol 92: 69–76, 1993

    Google Scholar 

  3. Hug V, Drewinko B, Hortobagyi GN, Blumenschein G: Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Res Treat 6: 237–240, 1985

    Google Scholar 

  4. Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333, 2002

    Google Scholar 

  5. Chen CL, Weiss NS, Newcomb P, Barlow W, White E: Hormone replacement therapy in relation to breast cancer. JAMA 287: 734–741, 2002

    Google Scholar 

  6. Newcomb PA, Titus-Ernstoff L, Egan KM et al.: Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11: 593–600, 2002

    Google Scholar 

  7. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 90: 814–823, 1998

    Google Scholar 

  8. Cleary MP, Maihle NJ: The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 216: 28–43, 1997

    Google Scholar 

  9. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047–1059, 1997

    Google Scholar 

  10. Kelsey JL, Bernstein L: Epidemiology and prevention of breast cancer. Annu Rev Public Health 17: 47–67, 1996

    Google Scholar 

  11. McGurrin JF, Doria MI Jr., Dawson PJ, Karrison T, Stein HO, Franklin WA: Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer 59: 1744–1750, 1987

    Google Scholar 

  12. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420–427, 1988

    Google Scholar 

  13. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981

    Google Scholar 

  14. Mirecka J, Korabiowska M, Schauer A: Correlation between the occurrence of Ki-67 antigen and clinical parameters in human breast carcinoma. Folia Histochem Cytobiol 31: 83–86, 1993

    Google Scholar 

  15. Meyer JS, Friedman E, McCrate MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983

    Google Scholar 

  16. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ: Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78: 1220–1228, 1996

    Google Scholar 

  17. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550–556, 2000

    Google Scholar 

  18. Muss HB, Kute TE, Case LD et al.: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64: 1894–1900, 1989

    Google Scholar 

  19. Romero H, Schneider J, Burgos J, Bilbao J, Rodriguez-Escudero FJ: S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers. Breast Cancer Res Treat 38: 265–275, 1996

    Google Scholar 

  20. Bloom HJG, Richardson WW, Harries EJ: Natural history of untreated breast cancer (1805-1933): comparison of untreated and treated cases according to histologic grade of malignancy. Br Med J 2: 213–221, 1962

    Google Scholar 

  21. Genestie C, Zafrani B, Asselain B et al.: Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res 18: 571–576, 1998

    Google Scholar 

  22. Clayton F: Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 68: 1309–1317, 1991

    Google Scholar 

  23. Goodson WH III, Moore DH II, Ljung BM et al.: The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat 59: 113–123, 2000

    Google Scholar 

  24. Molino A, Micciolo R, Turazza M et al.: Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74: 433–437, 1997

    Google Scholar 

  25. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585–592, 1996

    Google Scholar 

  26. Rudas M, Gnant MF, Mittlbock M et al.: Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32: 165–175, 1994

    Google Scholar 

  27. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421–428, 1991

    Google Scholar 

  28. Carter AP, Thompson RS, Bourdeau RV, Andenes J, Mustin H, Straley H: A clinically effective breast cancer screening program can be cost-effective, too. Prev Med 16: 19–34, 1987

    Google Scholar 

  29. Taplin SH, Mandelson MT, Anderman C et al.:Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 6: 625–631, 1997

    Google Scholar 

  30. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410, 1991

    Google Scholar 

  31. Lehr HA, Hansen DA, Kussick S et al.: Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol 30: 1314–1320, 1999

    Google Scholar 

  32. Weidner N, Moore DH II, Ljung BM et al.: Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells 142 N Oestreicher et al. with mitotic figure content and tumor grade. Am J Surg Pathol 17: 987–994, 1993

    Google Scholar 

  33. Andersen J, Poulsen HS: Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 64: 1901–1908, 1989

    Google Scholar 

  34. Ravn V, Havsteen H, Thorpe SM: Immunohistochemical evaluation of estrogen and progesterone receptors in paraffinembedded, formalin-fixed endometrial tissues: comparison with enzyme immunoassay and immunohistochemical analysis of frozen tissue. Mod Pathol 11: 709–715, 1998

    Google Scholar 

  35. Zafrani B, Aubriot MH, Mouret E et al.: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37: 536–545, 2000

    Google Scholar 

  36. Cattoretti G, Becker MH, Key G et al.: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363, 1992

    Google Scholar 

  37. Porter PL, Malone KE, Heagerty PJ et al.: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–225, 1997

    Google Scholar 

  38. Potischman N, Swanson CA, Siiteri P, Hoover RN: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 88: 756–758, 1996

    Google Scholar 

  39. Walker RA, Lees E, Webb MB, Dearing SJ: Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 74: 1796–1800, 1996

    Google Scholar 

  40. Reid SE, Murthy MS, Kaufman M, Scanlon EF: Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 83: 1037–1046, 1996

    Google Scholar 

  41. Olsson H, Jernstrom H, Alm P et al.: Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Treat 40: 187–196, 1996

    Google Scholar 

  42. de Waard F, Trichopoulos D: A unifying concept of the aetiology of breast cancer. Int J Cancer 41: 666–669, 1988

    Google Scholar 

  43. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD: Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women’s Health Study. Cancer 76: 275–283, 1995

    Google Scholar 

  44. Newman SC, Lees AW, Jenkins HJ: The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 26: 484–490, 1997

    Google Scholar 

  45. Yager JD: Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27: 67–73, 2000

    Google Scholar 

  46. Cobleigh MA, Norlock FE, Oleske DM, Starr A: Hormone replacement therapy and high S phase in breast cancer. JAMA 281: 1528–1530, 1999

    Google Scholar 

  47. Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16: 3115–3120, 1998

    Google Scholar 

  48. Friedman DR, Dubin N: Case-control evaluation of breast cancer screening efficacy. Am J Epidemiol 133: 974–984, 1991

    Google Scholar 

  49. LeBlanc ES, Viscoli CM, Henrich JB: Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. J Womens Health Gend Based Med 8: 815–823, 1999

    Google Scholar 

  50. Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K, Pommier RF: The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137: 1015–1019, 2002

    Google Scholar 

  51. Schairer C, Gail M, Byrne C et al.: Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91: 264–270, 1999

    Google Scholar 

  52. Grodstein F, Stampfer MJ, Colditz GA et al.: Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769–1775, 1997

    Google Scholar 

  53. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L: Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85: 11–17, 1995

    Google Scholar 

  54. Jernstrom H, Frenander J, Ferno M, Olsson H: Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80: 1453–1458, 1999

    Google Scholar 

  55. Nanda K, Bastian LA, Schulz K: Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186: 325–334, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

    Nina Oestreicher, Emily White, Kathleen E. Malone & Peggy L. Porter

  2. Department of Epidemiology, University of Washington, Seattle, WA, USA

    Nina Oestreicher, Emily White & Kathleen E. Malone

  3. Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

    Nina Oestreicher

  4. Department of Pathology, University of Washington, Seattle, WA, USA

    Peggy L. Porter

Authors
  1. Nina Oestreicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily White
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen E. Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peggy L. Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nina Oestreicher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oestreicher, N., White, E., Malone, K.E. et al. Hormonal Factors and Breast Tumor Proliferation: Do Factors that Affect Cancer Risk also Affect Tumor Growth?. Breast Cancer Res Treat 85, 133–142 (2004). https://doi.org/10.1023/B:BREA.0000025402.70958.3e

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000025402.70958.3e

Search

Navigation